TABLE 2.
Results for the method validation of F2-isoPs
| LLOD (pg inj.) | LLOQ (pg inj.) | Recoverya (%) | Intradayd | Interdaye | |||
| Precisionb (% CV) | Accuracyc (%) | Precision (% CV) | Accuracy (%) | ||||
| 8-iso-15(R)-PGF2α | 9.1 | 13.8 | 62.6 | 3.1 | −3.9 | 4.7 | −5.8 |
| 8-iso-PGF2α | 10.6 | 16.1 | 71.1 | 4.6 | −21.6 | 5.3 | −22.6 |
| 15(R)-PGF2α | 11.0 | 16.6 | 73.3 | 2.9 | 1.6 | 4.1 | 0.3 |
| iPF2α-IV | 7.5 | 11.3 | 59.1 | 2.6 | −2.6 | 3.4 | −4.6 |
| iPF2α-VI | 9.2 | 13.9 | 58.4 | 5.2 | 1.5 | 8.2 | 2.3 |
| 5-iPF2α-VI | 8.2 | 12.4 | 57.9 | 3.4 | 1.8 | 6.5 | 0.1 |
| (±)5-8,12-iso-iPF2α-VI | 13.8 | 21.0 | 71.2 | 4.1 | 9.2 | 8.1 | 4.1 |
LLOD, lower limit of detection; injected (inj.), .
a
Recovery was expressed as the mean value of data obtained from plasma samples spiked with 10 μl of working solutions containing 7 ng/ml, or 20 ng/ml of each analyte.
b
Precision is expressed as the mean value of data obtained from plasma samples spiked with 10 μl of working solutions containing 0 ng/ml, 7 ng/ml, or 20 ng/ml of each analyte.
c
Accuracy is expressed as the mean value of data obtained from plasma samples spiked with the 7 or 20 ng/ml working solutions.
d
n = 4 per concentration.
e
n = 12 per concentration.